
17th September, 2026

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, C-1,
Block G, Bandra Kurla Complex,
Bandra (E), Mumbai 400051

NSE SYMBOL: INVICTA

ISIN: INE0XJ501010

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Commencement of commercial operations of Centres at Shegaon Diagnostic LLP (a Subsidiary LLP), and Porteus Pathogenius LLP (a Step-Down Subsidiary LLP) of the Invicta Diagnostic Limited

In continuation with our earlier intimation dated 05th January, 2026 and 28th January, 2026 w.r.t Shegaon Diagnostic LLP and 01st June, 2026 and 12th June, 2026 w.r.t Porteus Pathogenius LLP and Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule III thereof, we wish to inform that the Company's Subsidiary LLP i.e. Shegaon Diagnostic LLP and Step-Down Subsidiary LLP i.e. Porteus Pathogenius LLP has established its diagnostic services centre at Shegaon and Pune Centre respectively and it has started commercial operations on 17th September, 2026.

The requisite details are enclosed herewith in the prescribed format in **Annexure-A**.

This is also being uploaded on the Company's website at www.pcdiagnostics.in

You are requested to take the same on record.

Thanking you.

Yours Faithfully,
For Invicta Diagnostic Limited

Sanket Vinod Jain
Managing Director
DIN: 08299039
Place: Mumbai

Annexure-A

Sr. No.	Particulars	Details of Shegaon Centre (Shegaon Diagnostic LLP, a subsidiary of the Company)	Details of Pune Centre (Porteus Pathogenius LLP, a Step-down Subsidiary of the Company)
1.	Existing capacity	The Company along with its subsidiaries currently operate 10 diagnostic centres and 1 centralised laboratory (Coexist with the centre).	The Company along with its subsidiaries currently operate 10 diagnostic centres and 1 centralised laboratory (Coexist with the centre).
2.	Existing capacity utilization	Capacity utilisation is not ascertainable in quantifiable terms, as the Company operates in the diagnostic services segment, which does not have a defined or standardised production capacity. The volume of services rendered varies based on patient inflow, test mix, diagnostic complexity, equipment usage duration and operating hours. Hence, capacity utilisation cannot be measured in conventional or numerical terms.	Capacity utilisation is not ascertainable in quantifiable terms, as the Company operates in the diagnostic services segment, which does not have a defined or standardised production capacity. The volume of services rendered varies based on patient inflow, test mix, equipment usage duration and operating hours. Hence, capacity utilisation cannot be measured in conventional or numerical terms.
3.	Proposed capacity addition	This capacity addition pertains to the commencement of new diagnostic modality, namely, CT scan services, at the Shegaon Centre (Shegaon Diagnostic LLP, a subsidiary of the Company).	This capacity addition pertains to the commencement of Pathology services, at the Pune Centre (Porteus Pathogenius LLP, a Step-Down Subsidiary of the Company).
4.	Period within which the proposed capacity is to be added	Commercial Operations started on 17 th September, 2026.	Commercial Operations started on 17 th September, 2026.
5.	Investment required	The investment is approximately Rs. 60 lakhs, which includes cost of equipment, installation and allied expenses.	The investment is approximately Rs. 10 lakhs, which includes cost of equipment, installation and allied expenses.
6.	Mode of financing	Company Funds.	Company Funds.
7.	Rationale	This commencement of diagnostic centre aligns with Invicta's long-term strategy to replicate its successful Mumbai operating model in high-potential urban markets, while partnering with reputed local clinicians to drive faster scale-up and deeper market penetration	This commencement of diagnostic centre aligns with Invicta's long-term strategy to replicate its successful Mumbai operating model in high-potential urban markets, while partnering with reputed local clinicians to drive faster scale-up and deeper market penetration

For Invicta Diagnostic Limited

Sanket Vinod Jain
Managing Director
DIN: 08299039
Place: Mumbai